Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

Walgreens Boots Alliance, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights – WBA

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Shareholders With Losses In Walgreens Boots Alliance, Inc. Are Urged to Join A Securities Fraud Lawsuit With The Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

SAN DIEGO, CA / ACCESSWIRE / August 21, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), have until Tuesday, September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v.

WBA INVESTOR DEADLINE: Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=96956&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Walgreens Boots Alliance, Inc.(WBA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors With Losses In Walgreens Boots Alliance Inc To Participate In A Securities Fraud Investigation

NEW YORK CITY, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.

Walgreens (WBA) Partners With BARDA to Boost Clinical Research

Key Points: Walgreens faces challenges after overexpanding, including buying Boots in Europe.

Walgreens (NASDAQ: WBA) Dividend Cuts Are Coming

Walgreens stock has been under pressure due to drug reimbursement issues and a poor acquisition. The company recently said it could look to sell its entire stake in VillageMD, which would be a good move.

With Shares Down Over 60%, Is Now the Time to Buy This Healthcare Stock?

Ford Motor Company

AT&T

Dividend stocks have a knack for handily outperforming non-payers over long periods. Form 13F filings allow investors to see what Wall Street's brightest investment minds bought and sold in the most recent quarter.

3 Brand-Name Ultra-High-Yield Dividend Stocks Billionaires Can't Stop Buying

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=96670&wire=1 or contact Joseph E. Levi, Esq.

Walgreens Boots Alliance, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - WBA

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholders of Walgreens Boots Alliance Inc To Join Securities Fraud Lawsuit

NEW YORK CITY, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Walgreens said it has signed a partnership with the U.S. government valued at $100 million for the drugstore giant to conduct clinical trials to aid in future emergency preparedness.

Walgreens Lands $100 Million U.S. Clinical Trials Partnership

Famed international pharmacy chain Walgreens is contemplating selling one of its most celebrated acquisitions— VillageMD, a value based primary care service the company acquired in 2021 for nearly $5.2 billion. Unfortunately, generating a profit from this acquisition has not been easy for the company, especially with growing economic headwinds, significant changes in pharmaceutical demand after the Covid-19 pandemic and an overall tumultuous business environment.

Walgreens' Potential Sale Of VillageMD Yet Again Signals The Challenges Of Care Delivery

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), today announced a strategic partnership to increase innovation in decentralized clinical trials as part of the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program. The program is designed to strengthen U.S. decentralized c.

Walgreens and BARDA Form Strategic Partnership to Strengthen Decentralized Clinical Trials Model and Reporting

NEW YORK , Aug. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Walgreens Boots Alliance, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - WBA

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Walgreens Boots Alliance, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBA

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Seeks Investors of Walgreens Boots Alliance Inc To Participate In An Investigation Of Suspected Securities Fraud

The pharmacy chain operator pays out a high-yield dividend. Although this looks tempting, there is quite a bit of risk attached to owning these shares.

Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Walgreens Stock

NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

CVS Health

Retail pharmacy chains such as Walgreens and CVS have pivoted from years of endless store expansions to shuttering hundreds of locations across the U.S. to shore up profits.  Among the biggest problems has been falling reimbursement rates for prescription drugs and several factors pressuring the front of the store, such as inflation and increased competition.

Here's why Walgreens and CVS retail pharmacies are struggling — and what they're doing to fix it

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants Shareholders of Walgreens Boots Alliance Inc To Join An Investigation Of Suspected Securities Fraud

Walgreens recently said it is selling shares of drug wholesaler Cencora. The company has been burning through cash in two of the past three quarters.

News for Walgreens Stock (WBA)